Based on these findings a dose of 75 mg every 2 weeks for 6 weeks followed by an upward titration to 150 mg every 2 weeks for those with LDL-C >50 mg/dl for the remainder of the study for this trial will be used. Based on population PK/PD modeling, a dose of 150 mg every 2 weeks in patients on a background of statins is estimated to be equivalent to approximately 80% of the maximal response for LDL-C lowering (-67%). Assuming an average LDL C at baseline of 100 mg/dL for HIV-infected individuals, the mean absolute LDL-C reduction is predicted to be approximately -60 mg/dL.